Orbimed Advisors LLC Iovance Biotherapeutics, Inc. Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $14.9 Million - $22.2 Million	2,700,000 Added 134.5%	4,707,458 $28.8 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $7.54 Million - $10.4 Million	-790,983 Reduced 28.27%	2,007,458 $19.2 Million
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $24.5 Million - $70.3 Million	-3,834,565 Reduced 57.81%	2,798,441 $30.9 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $3.66 Million - $5.64 Million	295,306 Added 4.66%	6,633,006 $110 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $5.09 Million - $8.49 Million	-307,400 Reduced 4.63%	6,337,700 $121 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $29.8 Million - $45 Million	1,096,774 Added 19.77%	6,645,100 $182 Million
Q4 2017 Feb 14, 2018	SELL	$6.65 - $9.25 $5.83 Million - $8.12 Million	-877,300 Reduced 13.65%	5,548,326 $44.4 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $28.6 Million - $54.9 Million	6,425,626	6,425,626 $49.8 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.24B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.